SkinBioTherapeutics (LON:SBTX) Trading Down 7.3% – What’s Next?

SkinBioTherapeutics plc (LON:SBTX) shares were down 7.3% during trading on Monday . The company traded as low as GBX 11 and last traded at GBX 11.25. Approximately 2,672,183 shares were traded during mid-day trading, a decline of 30% from the average session volume of 3,822,721 shares. The stock had previously closed at GBX 12.13.

SkinBioTherapeutics Price Performance

The company has a market capitalization of £26.60 million, a price-to-earnings ratio of -33.10 and a beta of 0.12. The company has a current ratio of 6.14, a quick ratio of 10.01 and a debt-to-equity ratio of 11.77. The company has a 50 day moving average price of GBX 9.87 and a 200 day moving average price of GBX 12.13.

SkinBioTherapeutics (LON:SBTX) last issued its quarterly earnings results on Monday, June 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. The firm had revenue of GBX 217 million for the quarter. SkinBioTherapeutics had a negative net margin of 8.73% and a negative return on equity of 5.25%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.